In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of Product Development, heads of regulatory affairs, and commercial directors from nasogastric tube producers, medical device OEMs, and enteral feeding solution suppliers were examples of supply-side sources. Critical care doctors, gastroenterologists, nurse practitioners, clinical nutrition specialists, hospital and health system procurement leads, administrators of long-term care facilities, and home healthcare agency managers were examples of demand-side sources. Primary research obtained information on clinical adoption patterns, pricing strategies, reimbursement dynamics (DRG coding for enteral feeding), and infection prevention methods. It also verified product pipeline timeframes and validated market segmentation.
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)
By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)
Global market valuation was derived through revenue mapping and procedure volume analysis. The methodology included:
Identification of 40+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America
Product mapping across Levin tubes, Salem sump tubes, Dobbhoff (small-bore) tubes, and other NG tube categories (radiopaque, weighted tip, anti-clog designs)
Analysis of reported and modeled annual revenues specific to nasogastric tube portfolios
Coverage of manufacturers representing 65-70% of global market share in 2024
Extrapolation using bottom-up (hospital admission volumes × tube utilization rates × ASP by country) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations